The GEO Group, Inc. (GEO) Forms $24.70 Double Bottom; Diplomat Pharmacy (DPLO) Shorts Raised By 17.29%

Diplomat Pharmacy, Inc. (NYSE:DPLO) Logo

The GEO Group, Inc. (GEO) formed double bottom with $22.48 target or 9.00% below today’s $24.70 share price. The GEO Group, Inc. (GEO) has $3.01 billion valuation. The stock decreased 0.84% or $0.21 during the last trading session, reaching $24.7. About 649,455 shares traded. The GEO Group, Inc. (NYSE:GEO) has declined 21.43% since June 14, 2017 and is downtrending. It has underperformed by 34.00% the S&P500. Some Historical GEO News: ; 09/04/2018 – NJ WARN NOTICE FOR LOGAN HALL/GEO GROUP AFFECTS 54 IN NEWARK; 26/04/2018 – GEO GROUP INC QTRLY NORMALIZED FFO OF $0.43 PER DILUTED SHARE; 04/05/2018 – GEO GROUP INC SAYS ON APRIL 30 ENTERED INTO THAT CERTAIN AMENDMENT NO.1 TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT – SEC FILING; 29/03/2018 – GEOAmey Joint Venture Signs Court Custody and Prisoner Escort Services Contract in Scotland; 26/04/2018 – GEO Group Sees 2018 Adj EPS $1.30-Adj EPS $1.38; 26/04/2018 – GEO Group 1Q Adjusted FFO 57c/Share; 06/03/2018 Geo Group Conference Call Set By Stuart Frankel for Mar. 14; 19/04/2018 – DJ GEO Group Inc, Inst Holders, 1Q 2018 (GEO); 09/04/2018 – NJ Warn Notices: Logan Hall/GEO Group, Inc. – 06/04/2018; 29/03/2018 – GEO GROUP INC – CONTRACT WILL HAVE A BASE TERM OF EIGHT YEARS EFFECTIVE JANUARY 26, 2019 WITH A RENEWAL OPTION PERIOD OF FOUR YEARS

Diplomat Pharmacy Inc (NYSE:DPLO) had an increase of 17.29% in short interest. DPLO’s SI was 7.40M shares in June as released by FINRA. Its up 17.29% from 6.31 million shares previously. With 1.03 million avg volume, 7 days are for Diplomat Pharmacy Inc (NYSE:DPLO)’s short sellers to cover DPLO’s short positions. The SI to Diplomat Pharmacy Inc’s float is 14.9%. The stock increased 2.36% or $0.61 during the last trading session, reaching $26.41. About 645,872 shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has risen 39.09% since June 14, 2017 and is uptrending. It has outperformed by 26.52% the S&P500. Some Historical DPLO News: ; 10/05/2018 – Chain Drug Rvw: Diplomat Pharmacy names Griffin CEO; 21/04/2018 – DJ Diplomat Pharmacy Inc, Inst Holders, 1Q 2018 (DPLO); 07/05/2018 – DIPLOMAT PHARMACY SEES FY ADJ EPS 87C TO 97C, EST. 93C; 07/05/2018 – Diplomat Pharmacy 1Q Loss/Shr 1c; 01/05/2018 – Diplomat to Participate in 43rd Annual Deutsche Bank Health Care Conference; 08/05/2018 – Diplomat Pharmacy Financial Chief Atul Kavthekar to Temporarily Assume Added CEO Responsibilities; 10/05/2018 – DIPLOMAT PHARMACY INC – BOARD WILL EXPAND TO EIGHT MEMBERS WITH GRIFFIN’S APPOINTMENT; 10/05/2018 – DIPLOMAT PHARMACY NAMES BRIAN GRIFFIN AS CEO & CHAIRMAN OF; 10/05/2018 – DIPLOMAT PHARMACY NAMES BRIAN GRIFFIN AS CEO & CHAIRMAN; 07/05/2018 – DIPLOMAT PHARMACY 1Q ADJ EPS 20C, EST. 21C

Among 17 analysts covering Diplomat Pharmacy (NYSE:DPLO), 8 have Buy rating, 0 Sell and 9 Hold. Therefore 47% are positive. Diplomat Pharmacy had 47 analyst reports since August 4, 2015 according to SRatingsIntel. On Thursday, January 25 the stock rating was upgraded by Credit Suisse to “Hold”. Cowen & Co maintained Diplomat Pharmacy, Inc. (NYSE:DPLO) on Thursday, November 3 with “Market Perform” rating. The firm has “Buy” rating given on Friday, March 2 by Deutsche Bank. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) has “Market Perform” rating given on Tuesday, November 7 by Leerink Swann. Mizuho maintained the shares of DPLO in report on Tuesday, November 7 with “Hold” rating. The company was maintained on Tuesday, February 27 by Needham. Barclays Capital initiated Diplomat Pharmacy, Inc. (NYSE:DPLO) rating on Wednesday, January 6. Barclays Capital has “Overweight” rating and $41 target. The firm earned “Neutral” rating on Tuesday, June 7 by Bank of America. The rating was upgraded by JP Morgan to “Overweight” on Thursday, May 10. The firm earned “Hold” rating on Tuesday, October 24 by Mizuho.

More news for Diplomat Pharmacy, Inc. (NYSE:DPLO) were recently published by: Prnewswire.com, which released: “Diplomat Grants CEO Brian Griffin Inducement Awards Pursuant To NYSE Rule 303A.08” on June 05, 2018. Digitaljournal.com‘s article titled: “Update: Lawsuit for Investors in NYSE: DPLO Shares Against Diplomat Pharmacy Inc Announced by Shareholders …” and published on June 04, 2018 is yet another important article.

Since March 9, 2018, it had 0 insider purchases, and 7 insider sales for $44.94 million activity. 2.15 million shares were sold by Hagerman Philip R, worth $44.40M. 13,875 shares valued at $335,806 were sold by Park Jeffrey G on Wednesday, May 23. The insider Wolin Benjamin sold 1,679 shares worth $40,744. $40,767 worth of Diplomat Pharmacy, Inc. (NYSE:DPLO) was sold by KLEPPER KENNETH O. Another trade for 1,680 shares valued at $40,765 was made by Benjamin Regina M. on Friday, June 1. Tomasello Shawn sold $40,766 worth of stock.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $1.96 billion. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It has a 115.83 P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Investors sentiment decreased to 1 in 2018 Q1. Its down 0.89, from 1.89 in 2017Q4. It turned negative, as 28 investors sold Diplomat Pharmacy, Inc. shares while 60 reduced holdings. 35 funds opened positions while 53 raised stakes. 54.74 million shares or 16.16% more from 47.12 million shares in 2017Q4 were reported. Phocas Financial owns 627,999 shares. Citadel Advisors Lc has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). 111,250 are owned by Mackay Shields Ltd Liability. Cortina Asset Mngmt Limited Co holds 0.91% or 924,173 shares in its portfolio. Alphamark Advisors Limited Liability Company invested in 0.35% or 41,046 shares. Moreover, Deutsche Financial Bank Ag has 0.01% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 767,597 shares. Tiaa Cref Investment Management Limited Liability Corp accumulated 371,295 shares. Castleark Mgmt Ltd Company invested in 0.13% or 204,140 shares. Federated Invsts Pa reported 1,662 shares. 116,129 were accumulated by Rhumbline Advisers. Geode Ltd Liability Corporation stated it has 400,929 shares. Koch Inc reported 36,077 shares. Thrivent Fincl For Lutherans reported 32,427 shares. Cubist Systematic Strategies Ltd Liability Co invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Aperio Gru Ltd Limited Liability Company has 21,030 shares for 0% of their portfolio.

Analysts await The GEO Group, Inc. (NYSE:GEO) to report earnings on August, 6. They expect $0.48 earnings per share, down 21.31% or $0.13 from last year’s $0.61 per share. GEO’s profit will be $58.57 million for 12.86 P/E if the $0.48 EPS becomes a reality. After $0.57 actual earnings per share reported by The GEO Group, Inc. for the previous quarter, Wall Street now forecasts -15.79% negative EPS growth.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Positions Chart